Modern Subunit Vaccines: Development, Components, and Research Opportunities

@article{Moyle2013ModernSV,
  title={Modern Subunit Vaccines: Development, Components, and Research Opportunities},
  author={Peter Michael Moyle and Istvan Toth},
  journal={ChemMedChem},
  year={2013},
  volume={8}
}
Traditional vaccines, based on the administration of killed or attenuated microorganisms, have proven to be among the most effective methods for disease prevention. Safety issues related to administering these complex mixtures, however, prevent their universal application. Through identification of the microbial components responsible for protective immunity, vaccine formulations can be simplified, enabling molecular‐level vaccine characterization, improved safety profiles, prospects to develop… 
Progress in Vaccine Development
  • P. Moyle
  • Medicine, Biology
    Current protocols in microbiology
  • 2015
TLDR
This unit provides an overview of the components that are used for the development of modern vaccines including an introduction to different vaccine types; techniques for identifying subunit antigens; vaccine delivery systems; and immunostimulatory agents (‘adjuvants’), which are fundamental for theDevelopment of effective subunit vaccines.
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
  • P. Moyle
  • Biology, Medicine
    Biotechnology advances
  • 2017
TLDR
Four protein-based adjuvants are reviewed, which can be genetically fused to antigens to enable recombinant production of antigen-adjuvant fusion proteins, with a focus on their mechanisms of action.
Chapter 4 – Vaccine Adjuvantsa
TLDR
To be maximally effective, adjuvants must be selected judiciously and formulated appropriately based on the desired immune response.
Adjuvant nanoformulations for tuberculosis vaccine delivery
TLDR
Due to the emergence of new diseases, reemerging diseases, and drug-resistant infections such as tuberculosis, the discovery of new vaccine candidates and adjuvants/adjuvant formulations is necessary.
Application of built-in adjuvants for epitope-based vaccines
TLDR
The current and prospective applications of these built-in adjuvants (i.e., biological carriers) are discussed to provide some references for the future design of epitope-based vaccines.
An Overview on Chitosan-Based Adjuvant/Vaccine Delivery Systems
TLDR
Chitosan has been one of the most attractive materials that has been investigated as vaccine adjuvant/delivery system, due to its promising features such as bioadhesivity, biocompatibility, biodegradability, and penetration enhancing activity, as well as bioactive properties (immunostimulatory, anti-inflammatory).
Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
TLDR
An overview of the current literature is provided to guide and focus rational particle-based vaccine design efforts, with specific emphasis on PRR-targeted adjuvants and particle physicochemical properties.
Developments in Vaccine Adjuvants.
TLDR
This chapter reviews the adjuvants that are available for use in human vaccines, such as alum, MF59, AS03, and AS01, and extensively discusses their composition, characteristics, mechanism of action, and effects on the immune system.
Cell-Penetrating Peptides: Efficient Vectors for Vaccine Delivery
TLDR
This review describes the different mechanisms of CPP intercellular uptake and various CPP-based vaccine delivery strategies.
Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
TLDR
Various TLR agonists utilized as immunostimulatory adjuvants are summarized and the development of techniques for generating adjuvant-antigen fusion vaccines incorporating peptide or protein antigens is focused on.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 253 REFERENCES
Method for the synthesis of highly pure vaccines using the lipid core peptide system
TLDR
The development of methods for the synthesis of highly pure LCP analogs using native chemical ligation and the addition of approximately 1% (w/v) sodium dodecyl sulfate (SDS) proved successful, enabling the synthesisation of two highly pure, tri‐epitopic Streptococcus pyogenes L CP analogs.
License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems.
  • C. Foged, J. Hansen, E. Agger
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2012
TLDR
The current status of lipid- and polymer-based particulate antigen delivery systems capable of stimulating CD8(+) T-cell immunity is reviewed with special focus on mechanisms of priming and pharmaceutical requirements for optimal activation of cytotoxic T-lymphocytes that can kill virus-infected or abnormal (cancer) cells.
Designing vaccines based on biology of human dendritic cell subsets.
TLDR
Increased understanding of the mechanisms of antigen presentation, particularly with the description of DC subsets with distinct functions, as well as their plasticity in responding to extrinsic signals, will permit us to design vaccines that will reprogram the immune system to intervene therapeutically in cancer, allergy, and autoimmunity.
Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.
TLDR
Targeting antigen to immune cells via PAMP-modified biomaterials is a new strategy to control the subsequent development of immunity and, in turn, effective vaccination.
Self-adjuvanting lipopeptide vaccines.
TLDR
The conjugation of immunostimulatory lipids to peptide antigens, to produce self-adjuvanting lipopeptide vaccines, has been tested in human clinical trials and appears to have a number of advantages over more traditional adjuvants.
Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists
TLDR
This review outlines how peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.
Use of defined TLR ligands as adjuvants within human vaccines
Summary:  Our improved understanding of how innate immune responses can be initiated and how they can shape adaptive B‐ and T‐cell responses is having a significant impact on vaccine development by
Vaccine adjuvants: putting innate immunity to work.
TLDR
There remains a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines, and the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens.
TLR ligand-peptide conjugate vaccines: toward clinical application.
TLDR
This review focuses on the different PRR families that can be exploited for the design of conjugates and explores the results obtained so far with PRR ligands conjugated to antigen.
Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.
TLDR
It is demonstrated that the immune response against the synthetic epitopes conjugated to tetanus toxoid can be suppressed by pre-existing immunity against this same carrier, which has important implications for the development of synthetic vaccines.
...
1
2
3
4
5
...